Blood biomarkers in ischemic stroke: potential role and challenges in clinical practice and research

Abstract Fast and accurate diagnosis of stroke is crucial for the immediate application of the right therapy to patients. However, rapid diagnosis is still a challenge since an ischemic stroke cannot be identified based only on clinical assessment. CT or MRI imaging is required to rule out hemorrhagic stroke since thrombolytic therapy can lead to increased intracranial bleeding and further aggravation of hemorrhagic stroke. In addition, clinical situations that imitate the signs and symptoms of stroke may also impede the rapid diagnosis and treatment of stroke victims. It is therefore of value to discover non-invasive tests that aim to quickly distinguish stroke from stroke mimics and distinguish ischemic from hemorrhagic stroke. Identifying blood biomarkers of stroke is an active area of research since their potential use is not limited to diagnosis and differentiation, but can be applied to prognosis and patient monitoring – monitoring the effectiveness of applied therapy and/or diagnose possible complications. However, their use has been limited so far not only for reasons related to patients and the disease (heterogeneity of stroke etiology, the complexity of the ischemic cascade, the impact of the blood–brain barrier (BBB) on diffusion of blood biomarkers, and difficulties in obtaining consent from stroke patients) but also for reasons that related to laboratory measurement of these biomarkers (pre-analytical and analytical issues as well as interpretation of laboratory measurements). Until today, many biomarkers have been identified, however none so far have shown sufficient sensitivity and specificity in order to be used in the clinical setting. In this review, we will focus on ischemic stroke and we aim to highlight these problems and also investigate if these are due to stroke complexity or due to our limited knowledge of pre-analytical requirements for many of these molecules and the questionable quality of the assays used.

[1]  Guohong Li,et al.  Inflammatory mechanisms in ischemic stroke: role of inflammatory cells , 2010, Journal of leukocyte biology.

[2]  W Greg Miller,et al.  Harmonization of test results: what are the challenges; how can we make it better? , 2014, Clinical chemistry.

[3]  D. Lillicrap,et al.  Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. , 1999, Blood.

[4]  A. Reininger.  Function of von Willebrand factor in haemostasis and thrombosis , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  Ramón A Durazo-Arvizu,et al.  Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-hydroxyvitamin D data: a case study of the program's potential for national nutrition and health surveys. , 2013, The American journal of clinical nutrition.

[6]  Y. T. Wang,et al.  Excitotoxicity and stroke: Identifying novel targets for neuroprotection , 2014, Progress in Neurobiology.

[7]  R. Ransohoff,et al.  Development, maintenance and disruption of the blood-brain barrier , 2013, Nature Medicine.

[8]  A. Šimundić,et al.  Diagnostic and prognostic role of resistin and copeptin in acute ischemic stroke , 2017, Topics in stroke rehabilitation.

[9]  B. Sola,et al.  Reduction of cortical infarction and impairment of apoptosis in NGF-transgenic mice subjected to permanent focal ischemia. , 1998, Brain research. Molecular brain research.

[10]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[11]  M. Moskowitz,et al.  Pathobiology of ischaemic stroke: an integrated view , 1999, Trends in Neurosciences.

[12]  A. Chauhan,et al.  Abbreviations used: AD- , 2022 .

[13]  Michael D Hill,et al.  Diagnostic biomarkers for stroke: a stroke neurologist's perspective. , 2005, Clinical chemistry.

[14]  M. Hennerici,et al.  Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke. , 1995, Stroke.

[15]  G. Rosenberg.  Matrix metalloproteinases in neuroinflammation , 2002, Glia.

[16]  B. Palmieri,et al.  Oxidative stress tests: overview on reliability and use. Part II. , 2007, European review for medical and pharmacological sciences.

[17]  K. Furie,et al.  Molecular biomarkers in stroke diagnosis and prognosis. , 2009, Biomarkers in medicine.

[18]  P. Deyn,et al.  The complexity of neurobiological processes in acute ischemic stroke , 2009, Clinical Neurology and Neurosurgery.

[19]  P. Mecocci,et al.  Potential markers of oxidative stress in stroke. , 2005, Free radical biology & medicine.

[20]  Pedro Larrañaga,et al.  A review of feature selection techniques in bioinformatics , 2007, Bioinform..

[21]  P. Deyn,et al.  Clinical and biochemical diagnosis of small-vessel disease in acute ischemic stroke , 2009, Journal of the Neurological Sciences.

[22]  M. Panteghini,et al.  Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase. , 2013, Clinical biochemistry.

[23]  A. Buchan,et al.  Neurological complications of acute ischaemic stroke , 2011, The Lancet Neurology.

[24]  Dr Ferdiye Taner,et al.  The enzyme-linked immunosorbent assay (ELISA). , 1976, Bulletin of the World Health Organization.

[25]  M. Tymianski,et al.  Calcium, ischemia and excitotoxicity. , 2010, Cell calcium.

[26]  R. Rodrigo,et al.  Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic opportunities. , 2013, CNS & neurological disorders drug targets.

[27]  J. Struck,et al.  Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. , 2006, Clinical chemistry.

[28]  G. Sutherland,et al.  Primary intracerebral hemorrhage: pathophysiology. , 2005, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques.

[29]  J. Margolick,et al.  Multisite Comparison of High-Sensitivity Multiplex Cytokine Assays , 2011, Clinical and Vaccine Immunology.

[30]  D. Janigro,et al.  Understanding the Physiology of the Blood-Brain Barrier: In Vitro Models. , 1998, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[31]  Charles J Malemud,et al.  Matrix metalloproteinases (MMPs) in health and disease: an overview. , 2006, Frontiers in bioscience : a journal and virtual library.

[32]  P. Gorelick.  Lipoprotein-associated phospholipase A2 and risk of stroke. , 2008, The American journal of cardiology.

[33]  D. Wagner,et al.  Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. , 2005, Analytical biochemistry.

[34]  Mario Plebani,et al.  Harmonization in laboratory medicine: Requests, samples, measurements and reports , 2016, Critical reviews in clinical laboratory sciences.

[35]  E. Favaloro,et al.  Towards improved diagnosis of von Willebrand disease: comparative evaluations of several automated von Willebrand factor antigen and activity assays. , 2014, Thrombosis research.

[36]  J. Bogousslavsky,et al.  The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. , 1988, Stroke.

[37]  D. Wagner,et al.  An Emerging Target in Stroke Therapy , 2012 .

[38]  P. Persson,et al.  The neurovascular unit – concept review , 2014, Acta physiologica.

[39]  A. Twijnstra,et al.  Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. , 2004, Clinical chemistry.

[40]  J. Montaner,et al.  C‐reactive protein in the detection of post‐stroke infections: systematic review and individual participant data analysis , 2017, Journal of neurochemistry.

[41]  A. Hall,et al.  Serum 99th centile values for two heart-type fatty acid binding protein assays , 2009, Annals of clinical biochemistry.

[42]  C. Blomstrand,et al.  Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.

[43]  P. Sandercock,et al.  The Use of Blood Biomarkers to Predict Poor Outcome After Acute Transient Ischemic Attack or Ischemic Stroke , 2012, Stroke.

[44]  C. Hayward,et al.  Technological advances in diagnostic testing for von Willebrand disease: new approaches and challenges , 2014, International journal of laboratory hematology.

[45]  C. Casari,et al.  von Willebrand factor: the old, the new and the unknown , 2012, Journal of thrombosis and haemostasis : JTH.

[46]  Lu Tian,et al.  The estimation of calibration equations for variables with heteroscedastic measurement errors , 2014, Statistics in medicine.

[47]  W. Kuis,et al.  Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. , 2005, Journal of immunological methods.

[48]  Eng H. Lo,et al.  The Science of Stroke: Mechanisms in Search of Treatments , 2010, Neuron.

[49]  F. Sharp,et al.  Biomarker Panels in Ischemic Stroke , 2015, Stroke.

[50]  W. Dröge.  Free radicals in the physiological control of cell function. , 2002, Physiological reviews.

[51]  R. Woltjer,et al.  The Translational Significance of the Neurovascular Unit* , 2016, The Journal of Biological Chemistry.

[52]  Fengguo Xu,et al.  Discovery of Metabolite Biomarkers for Acute Ischemic Stroke Progression. , 2017, Journal of proteome research.

[53]  G A Nagana Gowda,et al.  Biomarker Discovery and Translation in Metabolomics. , 2013, Current Metabolomics.

[54]  R. Christenson,et al.  Point: Put simply, standardization of cardiac troponin I is complicated. , 2012, Clinical chemistry.

[55]  M. Doménech,et al.  Determination of the biological variation of S100β and lactate dehydrogenase in disease-free patients with malignant melanoma , 2012, Clinical chemistry and laboratory medicine.

[56]  S. Loening,et al.  Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. , 1997, Clinical biochemistry.

[57]  S. Duffy,et al.  Von Willebrand factor and risk of ischemic stroke , 1997, Neurology.

[58]  M. Kaste,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.

[59]  Taura L. Barr,et al.  Cytokines: their role in stroke and potential use as biomarkers and therapeutic targets. , 2014, Aging and disease.

[60]  M. Skalej,et al.  Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke , 2006, Clinical Neurology and Neurosurgery.

[61]  J. Broderick,et al.  Heart disease and stroke. , 1993, Heart disease and stroke : a journal for primary care physicians.

[62]  Richard D. Wilson.  Mortality and cost of pneumonia after stroke for different risk groups. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[63]  P. Carmeliet,et al.  Protective Role of Reactive Astrocytes in Brain Ischemia , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[64]  Maiken Nedergaard,et al.  The Glymphatic System: A Beginner’s Guide , 2015, Neurochemical Research.

[65]  D. Laskowitz,et al.  Early biomarkers of stroke. , 2003, Clinical chemistry.

[66]  E. Ranzato,et al.  Emerging roles for HMGB1 protein in immunity, inflammation, and cancer , 2015, ImmunoTargets and therapy.

[67]  Zamir Merali,et al.  Evolution of blood-brain-barrier permeability after acute ischemic stroke , 2017, PloS one.

[68]  L. Kappelle,et al.  Complications of Acute Ischaemic Stroke , 1998, Cerebrovascular Diseases.

[69]  P Trouillas,et al.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. , 1998, Lancet.

[70]  C. Sudlow,et al.  Inflammatory Markers and Poor Outcome after Stroke: A Prospective Cohort Study and Systematic Review of Interleukin-6 , 2009, PLoS medicine.

[71]  D. Laskowitz,et al.  Clinical application of blood biomarkers in cerebrovascular disease , 2010, Expert review of neurotherapeutics.

[72]  M. Elkind,et al.  Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke , 2016, Nature Reviews Neurology.

[73]  F Dati,et al.  Standardization activities for harmonization of test results. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[74]  Xiaoming Hu,et al.  Functional Role of Regulatory Lymphocytes in Stroke: Facts and Controversies , 2015, Stroke.

[75]  A. Chauhan,et al.  von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. , 2009, Blood.

[76]  J. Y. Kim,et al.  Innate inflammatory responses in stroke: mechanisms and potential therapeutic targets. , 2014, Current medicinal chemistry.

[77]  Lawrence D. True,et al.  Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents , 2010, Clinical Cancer Research.

[78]  N. Abbott.  Blood–brain barrier structure and function and the challenges for CNS drug delivery , 2013, Journal of Inherited Metabolic Disease.

[79]  J. Kline,et al.  Standardizing the D-dimer Assay: Proposing the D-dimer International Managed Ratio. , 2015, Clinical chemistry.

[80]  A. Yaman,et al.  Biological Variation and Reference Change Value Data for Serum Neuron‐Specific Enolase in a Turkish Population , 2016, Journal of clinical laboratory analysis.

[81]  H. Kamel,et al.  Brain-immune interactions and ischemic stroke: clinical implications. , 2012, Archives of neurology.

[82]  H. L. Bleich,et al.  The Harvard Cooperative Stroke Registry , 1978, Neurology.

[83]  R. Mcpherson,et al.  Widely Used Types and Clinical Applications of D-Dimer Assay. , 2016, Laboratory medicine.

[84]  Laurie A. Theeke,et al.  C-reactive protein and long-term ischemic stroke prognosis , 2014, Journal of Clinical Neuroscience.

[85]  P. Nederkoorn,et al.  Post-stroke infection: A systematic review and meta-analysis , 2011, BMC neurology.

[86]  H. Shang,et al.  Biological variation of serum neuron‐specific enolase and carbohydrate antigen 724 tumor markers , 2018, Journal of clinical laboratory analysis.

[87]  G. Hamann,et al.  Glial Fibrillary Acidic Protein Serum Levels Distinguish between Intracerebral Hemorrhage and Cerebral Ischemia in the Early Phase of Stroke. , 2017, Clinical chemistry.

[88]  S. Lakhan,et al.  Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke , 2013, Front. Neurol..

[89]  S. Levine,et al.  Is asymptomatic hemorrhagic transformation really innocuous? , 2012, Neurology.

[90]  A. Demchuk,et al.  Asymptomatic Hemorrhage After Thrombolysis May Not Be Benign: Prognosis by Hemorrhage Type in the Canadian Alteplase for Stroke Effectiveness Study Registry , 2007, Stroke.

[91]  Xinming Ma,et al.  Biological variations of seven tumor markers. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[92]  M. D. de Maat.  Effects of diet, drugs, and genes on plasma fibrinogen levels. , 2001, Annals of the New York Academy of Sciences.

[93]  A. Słowik,et al.  Serum interleukin-6 predicts cortisol release in acute stroke patients , 2004, Journal of endocrinological investigation.

[94]  G. Murray,et al.  Medical complications after stroke: a multicenter study. , 2000, Stroke.

[95]  D. Giannessi,et al.  Matrix metalloprotease-2 and -9 concentration and activity in serum and culture medium samples: a methodological reappraisal , 2007, Clinical chemistry and laboratory medicine.

[96]  J. Barrett,et al.  von Willebrand Factor and Factor VIII: C in Acute Cerebrovascular Disease , 1997, Thrombosis and Haemostasis.

[97]  F. Leebeek,et al.  High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke: Influence of ADAMTS13, Inflammation, and Genetic Variability , 2006, Stroke.

[98]  P. Koudstaal,et al.  C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death , 2009, Journal of Neurology.

[99]  Justin A. Sattin,et al.  The Promise and Potential Pitfalls of Serum Biomarkers for Ischemic Stroke and Transient Ischemic Attack , 2008, The neurologist.

[100]  M. Pepys,et al.  Human plasma fibrinogen is synthesized in the liver. , 2007, Blood.

[101]  D. Sander,et al.  Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members , 2005, Stroke.

[102]  P. Lescuyer,et al.  Heart-Fatty Acid-Binding Protein as a Marker for Early Detection of Acute Myocardial Infarction and Stroke , 2012, Molecular Diagnosis.

[103]  S. Pedraza,et al.  Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke , 2004, Stroke.

[104]  G. Jickling,et al.  Ischemic stroke biomarkers in blood. , 2013, Biomarkers in medicine.

[105]  Masaru Tomita,et al.  Systems Biology, Metabolomics, and Cancer Metabolism , 2012, Science.

[106]  R. Wolfert,et al.  Biochemical differences in the mass and activity tests of lipoprotein-associated phospholipase A2 explain the discordance in results between the two assay methods. , 2017, Clinical biochemistry.

[107]  J. Arenillas,et al.  Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke , 2003, Circulation.

[108]  G. Moseley,et al.  Multiplex Cytokine Concentration Measurement: How Much Do the Medium and Handling Matter? , 2013, Mediators of inflammation.

[109]  Quanwei He,et al.  Potential biomarkers for predicting hemorrhagic transformation of ischemic stroke , 2018, The International journal of neuroscience.

[110]  David M Bunk,et al.  Roadmap for harmonization of clinical laboratory measurement procedures. , 2011, Clinical chemistry.

[111]  Luis Cano,et al.  Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study , 2017, Stroke.

[112]  A. Demchuk,et al.  Hyperfibrinogenemia and functional outcome from acute ischemic stroke. , 2009, Stroke.

[113]  F. Spener,et al.  Release of brain–type and heart–type fatty acid–binding proteins in serum after acute ischaemic stroke , 2005, Journal of Neurology.

[114]  M. Casula,et al.  Update on Inflammatory Biomarkers and Treatments in Ischemic Stroke , 2016, International journal of molecular sciences.

[115]  K. Chapman,et al.  The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights , 2011, Molecular and Cellular Endocrinology.

[116]  H. Deckmyn,et al.  Inhibitors of Platelet Adhesion to VWF and Collagen , 2017 .

[117]  M. Di Napoli,et al.  Is plasma fibrinogen useful in evaluating ischemic stroke patients?: why, how, and when. , 2009, Stroke.

[118]  Peter Sandercock,et al.  Blood Biomarkers in the Diagnosis of Ischemic Stroke: A Systematic Review , 2008, Stroke.

[119]  S. Goto.  Role of von Willebrand factor for the onset of arterial thrombosis. , 2001, Clinical laboratory.

[120]  S. Kasner,et al.  Clinical Usefulness of a Biomarker-Based Diagnostic Test for Acute Stroke: The Biomarker Rapid Assessment in Ischemic Injury (BRAIN) Study , 2009, Stroke.

[121]  V. Bartoš,et al.  The comparability of different neuron-specific enolase immunoassays and its impact on external quality assessment system , 2007 .

[122]  W. Kuis,et al.  Simultaneous Detection of 15 Human Cytokines in a Single Sample of Stimulated Peripheral Blood Mononuclear Cells , 2003, Clinical Diagnostic Laboratory Immunology.

[123]  M. A. Moro,et al.  The Prediction of Malignant Cerebral Infarction by Molecular Brain Barrier Disruption Markers , 2005, Stroke.

[124]  G. Rosenberg,et al.  Matrix metalloproteinases as therapeutic targets for stroke , 2015, Brain Research.

[125]  K. Lambertsen,et al.  Inflammatory Cytokines in Experimental and Human Stroke , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[126]  Nader Rifai,et al.  Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. , 2003, Clinical chemistry.

[127]  E. Lo,et al.  Mechanisms and markers for hemorrhagic transformation after stroke. , 2008, Acta neurochirurgica. Supplement.

[128]  I. Zegers,et al.  Standardization of protein biomarker measurements: Is it feasible? , 2010, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[129]  C. Litwin,et al.  Heterophile Antibody Interference in a Multiplexed Fluorescent Microsphere Immunoassay for Quantitation of Cytokines in Human Serum , 2004, Clinical Diagnostic Laboratory Immunology.

[130]  M. Bennett,et al.  Blood-brain barrier dysfunction and recovery after ischemic stroke , 2017, Progress in Neurobiology.

[131]  J. Losy,et al.  Adhesion molecules of immunoglobulin gene superfamily in stroke. , 2002, Folia morphologica.

[132]  A. Grau,et al.  Inflammation and Infections as Risk Factors for Ischemic Stroke , 2003, Stroke.

[133]  D. Choi,et al.  Brain tissue responses to ischemia. , 2000, The Journal of clinical investigation.

[134]  M. Fornage,et al.  Basic concepts and potential applications of genetics and genomics for cardiovascular and stroke clinicians: a scientific statement from the American Heart Association. , 2015, Circulation. Cardiovascular genetics.

[135]  Y. Shoshan,et al.  Serum S100B levels after meningioma surgery: A comparison of two laboratory assays , 2008, BMC clinical pathology.

[136]  Cumara B. O’Carroll,et al.  Cardioembolic Stroke , 2017, Continuum.

[137]  D. Laskowitz,et al.  Panel of Biomarkers Predicts Stroke , 2005, Annals of the New York Academy of Sciences.

[138]  S. Fumagalli,et al.  The Ischemic Environment Drives Microglia and Macrophage Function , 2015, Front. Neurol..

[139]  Joachim Thiery,et al.  Effect of biobanking conditions on short-term stability of biomarkers in human serum and plasma , 2014, Clinical chemistry and laboratory medicine.

[140]  M. Furlan,et al.  Von Willebrand factor: molecular size and functional activity , 1996, Annals of Hematology.

[141]  P. McColgan,et al.  Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review. , 2012, British journal of clinical pharmacology.

[142]  M. Woodward,et al.  Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke , 2005, Stroke.

[143]  D. Attwell,et al.  Glial and neuronal control of brain blood flow , 2022 .

[144]  Á. Chamorro,et al.  The harms and benefits of inflammatory and immune responses in vascular disease. , 2006, Stroke.

[145]  C. Yoon,et al.  Premorbid warfarin use and lower D‐dimer levels are associated with a spontaneous early improvement in an atrial fibrillation‐related stroke , 2012, Journal of thrombosis and haemostasis : JTH.

[146]  J. Danesh,et al.  Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies , 2010, The Lancet.

[147]  Bolanle M Famakin.  The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review. , 2014, Aging and disease.

[148]  I. Žitňanová,et al.  Oxidative Stress Markers and Their Dynamic Changes in Patients after Acute Ischemic Stroke , 2016, Oxidative medicine and cellular longevity.

[149]  B. Rosen,et al.  Role of matrix metalloproteinases in delayed cortical responses after stroke , 2006, Nature Medicine.

[150]  T. Neumann-Haefelin,et al.  S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion , 2003, Journal of neurology, neurosurgery, and psychiatry.

[151]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[152]  T. Toyo’oka,et al.  Biomarker discovery in biological specimens (plasma, hair, liver and kidney) of diabetic mice based upon metabolite profiling using ultra-performance liquid chromatography with electrospray ionization time-of-flight mass spectrometry. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[153]  T. Cronberg,et al.  Serum neuron specific enolase – impact of storage and measuring method , 2014, BMC Research Notes.

[154]  J. Arenillas,et al.  Matrix Metalloproteinase Expression After Human Cardioembolic Stroke: Temporal Profile and Relation to Neurological Impairment , 2001, Stroke.

[155]  J. Weatherbee,et al.  Cytokine assays and their limitations. , 1996, Alimentary pharmacology & therapeutics.

[156]  N. Abbott.  Anatomy and Physiology of the Blood–Brain Barriers , 2014 .

[157]  M. Mazzola,et al.  Frequency and Determinants for Hemorrhagic Transformation of Cerebral Infarction , 2009, Neuroepidemiology.

[158]  Analytical and biological variation of biomarkers of oxidative stress during the menstrual cycle. , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[159]  Mary P. Stenzel-Poore,et al.  Mechanisms of ischemic brain damage , 2008, Neuropharmacology.

[160]  E. H. Esmail,et al.  Matrix Metalloproteinase-9 and Recovery of Acute Ischemic Stroke. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[161]  A. Algra,et al.  High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. , 2012, Blood.

[162]  B. Palmieri,et al.  Oxidative stress tests: overview on reliability and use. Part I. , 2007, European review for medical and pharmacological sciences.

[163]  W. Miller.  Harmonization: Its Time Has Come. , 2017, Clinical chemistry.

[164]  P. Whincup,et al.  Copeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study , 2016, Diabetologia.

[165]  W. Freeman,et al.  Prevention of Cardioembolic Stroke , 2011, Neurotherapeutics.

[166]  M. Cavaglià,et al.  Peripheral markers of blood-brain barrier damage. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[167]  M. Woodward,et al.  Associations of Proinflammatory Cytokines With the Risk of Recurrent Stroke , 2008, Stroke.

[168]  L. R. Padial,et al.  Potential blood biomarkers for stroke , 2012, Expert review of proteomics.

[169]  M. Aries,et al.  Cerebral Autoregulation in Stroke: A Review of Transcranial Doppler Studies , 2010, Stroke.

[170]  Janne Lehtiö,et al.  Mass spectrometry-based plasma proteomics: state of the art and future outlook , 2014, Expert review of proteomics.

[171]  Yetrib Hathout,et al.  Proteomic methods for biomarker discovery and validation. Are we there yet? , 2015, Expert review of proteomics.

[172]  W. Hacke,et al.  Hemorrhagic Transformation of Ischemic Brain Tissue: Asymptomatic or Symptomatic? , 2001, Stroke.

[173]  G. D. De Marchis,et al.  Copeptin adds prognostic information after ischemic stroke , 2013, Neurology.

[174]  M. Di Napoli,et al.  Prognostic Influence of Increased C-Reactive Protein and Fibrinogen Levels in Ischemic Stroke , 2001, Stroke.

[175]  L. Stead,et al.  Neuron-Specific Enolase as a Marker for Acute Ischemic Stroke: A Systematic Review , 2005, Cerebrovascular Diseases.

[176]  P. Mariën,et al.  Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[177]  F. Sharp,et al.  Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke , 2016, Front. Cell. Neurosci..

[178]  Z. Ruggeri.  Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. , 2001, Best practice & research. Clinical haematology.

[179]  E. Warburton,et al.  Inflammation and ischaemic stroke , 2007, Current opinion in neurology.

[180]  D. Wagner,et al.  Plasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation , 2005 .

[181]  M. Wiesmann,et al.  S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. , 1997, Stroke.

[182]  D. Holtzman,et al.  Reperfusion Differentially Induces Caspase-3 Activation in Ischemic Core and Penumbra After Stroke in Immature Brain , 2003, Stroke.

[183]  A. Tort,et al.  Influence of anticoagulants on the measurement of S100B protein in blood. , 2003, Clinical biochemistry.

[184]  Wenzhi Wang,et al.  Ischemic Stroke: From Next Generation Sequencing and GWAS to Community Genomics? , 2015, Omics : a journal of integrative biology.

[185]  Ping Cai,et al.  Recombinant ADAMTS13 reduces tissue plasminogen activator‐induced hemorrhage after stroke in mice , 2013, Annals of neurology.

[186]  B. Palmieri,et al.  Oxidative stress detection : what for ? Part II , 2022 .

[187]  Ronney B Panerai,et al.  Effects of cerebral ischemia on human neurovascular coupling, CO2 reactivity, and dynamic cerebral autoregulation. , 2015, Journal of applied physiology.

[188]  À. Rovira,et al.  Caspase-3 is related to infarct growth after human ischemic stroke , 2008, Neuroscience Letters.

[189]  Thomas Brott,et al.  The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study. , 2005, Annals of emergency medicine.

[190]  P. Lyden,et al.  Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. , 1993, Cerebrovascular and brain metabolism reviews.

[191]  G. Wallstrom,et al.  Biomarker Discovery for Heterogeneous Diseases , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[192]  Donald H. Lee,et al.  Cerebral blood flow threshold of ischemic penumbra and infarct core in acute ischemic stroke: a systematic review. , 2006, Stroke.

[193]  Jean-Charles Sanchez,et al.  Fatty Acid Binding Protein as a Serum Marker for the Early Diagnosis of Stroke , 2004, Molecular & Cellular Proteomics.

[194]  S Claiborne Johnston,et al.  Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling , 2009, The Lancet Neurology.

[195]  E. Engvall,et al.  Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. , 1971, Immunochemistry.

[196]  V. Hachinski,et al.  Complications of acute stroke , 1992, The Lancet.

[197]  M. Cavaglià,et al.  Peripheral markers of brain damage and blood-brain barrier dysfunction. , 2003, Restorative neurology and neuroscience.

[198]  D. Pisetsky,et al.  The Role of HMGB1 in the Pathogenesis of Inflammatory and Autoimmune Diseases , 2014, Molecular medicine.

[199]  Jun Chen,et al.  Programmed Cell Death in Cerebral Ischemia , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[200]  D. Subirá,et al.  IL-6 as a biomarker of ischemic cerebrovascular disease. , 2008, Biomarkers in medicine.

[201]  Kahraman Tanriverdi,et al.  The role of the blood transcriptome in innate inflammation and stroke , 2010, Annals of the New York Academy of Sciences.

[202]  Ting-Yim Lee,et al.  Hemorrhagic Transformation of Ischemic Stroke: Prediction with CT , 2009 .

[203]  A. Chauhan,et al.  Systemic antithrombotic effects of ADAMTS13 , 2006, The Journal of experimental medicine.

[204]  W. Hermens,et al.  Increased fatty acid-binding protein concentration in plasma of patients with chronic renal failure. , 1997, Clinical chemistry.

[205]  B. Siesjö,et al.  Thresholds in cerebral ischemia - the ischemic penumbra. , 1981, Stroke.

[206]  V. Seyfert-Margolis,et al.  Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays , 2009, BMC Immunology.

[207]  C. Molina,et al.  Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers , 2008, Stroke.

[208]  J. Eikenboom,et al.  Developments in the diagnostic procedures for von Willebrand disease , 2016, Journal of thrombosis and haemostasis : JTH.

[209]  I. Shelef,et al.  Anatomy and physiology of the blood-brain barrier. , 2015, Seminars in cell & developmental biology.

[210]  Anne M Manicone,et al.  Matrix metalloproteinases as modulators of inflammation. , 2008, Seminars in cell & developmental biology.

[211]  R. Ekins.  Immunoassay standardization. , 1991, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[212]  F. Marín,et al.  Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. , 2005, Thrombosis research.

[213]  L. Stead,et al.  Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. , 2011, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[214]  M. Hennerici,et al.  Classification of Stroke Subtypes , 2009, Cerebrovascular Diseases.

[215]  L. Kaczmarek,et al.  MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke , 2013, Molecular Neurobiology.

[216]  G. Tsivgoulis,et al.  Plasma Glial Fibrillary Acidic Protein in the Differential Diagnosis of Intracerebral Hemorrhage , 2017, Stroke.

[217]  L. Csiba,et al.  Factors influencing hemorrhagic transformation in ischemic stroke: a clinicopathological comparison , 2006, European journal of neurology.

[218]  Martin Dichgans,et al.  Advances in Genomic Analysis of Stroke: What Have We Learned and Where Are We Headed? , 2010, Stroke.

[219]  K. Hossmann.  Experimental models for the investigation of brain ischemia. , 1998, Cardiovascular research.

[220]  E. Stein.  Lipoprotein-associated phospholipase A₂ measurements: mass, activity, but little productivity. , 2012, Clinical chemistry.

[221]  J. Baron,et al.  Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery , 2008, British journal of pharmacology.

[222]  P. Rieckmann,et al.  A longitudinal prospective study of soluble adhesion molecules in acute stroke. , 1998, Stroke.

[223]  C. Legnani,et al.  Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded , 2012, Haematologica.

[224]  H D Humes,et al.  Structure and function of cell adhesion molecules. , 1999, The American journal of medicine.

[225]  W. Hooper,et al.  Interference in microsphere flow cytometric multiplexed immunoassays for human cytokine estimation. , 2006, Cytokine.

[226]  A. Šimundić,et al.  International Survey on D-Dimer Test Reporting: A Call for Standardization , 2015, Seminars in Thrombosis & Hemostasis.

[227]  Lyden Pd,et al.  Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. , 1993, Cerebrovascular and brain metabolism reviews.

[228]  F. de Pasquale,et al.  Cerebrospinal fluid and serum neuron‐specific enolase concentrations in a normal population * , 2005, European journal of neurology.

[229]  R. Tracy,et al.  Longitudinal Stability of Coagulation, Fibrinolysis, and Inflammation Factors in Stored Plasma Samples , 2001, Thrombosis and Haemostasis.

[230]  A. Grau,et al.  Common infections and the risk of stroke , 2010, Nature Reviews Neurology.

[231]  M. Cipolla,et al.  SKCa and IKCa Channels, Myogenic Tone, and Vasodilator Responses in Middle Cerebral Arteries and Parenchymal Arterioles: Effect of Ischemia and Reperfusion , 2009, Stroke.

[232]  P. Langhorne,et al.  Confirmation Using Routine Clinical Assays , 2006 .

[233]  J. Garthwaite,et al.  Serum S-100 Protein, Relationship to Clinical Outcome in Acute Stroke , 1997, Annals of clinical biochemistry.

[234]  N. Morgenthaler,et al.  The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department , 2012, BMC Medicine.

[235]  V. Yong,et al.  Metalloproteinases: Mediators of Pathology and Regeneration in the CNS , 2005, Nature Reviews Neuroscience.

[236]  R. Al‐Shahi Salman,et al.  Epidemiology of Intracerebral Haemorrhage. , 2015, Frontiers of neurology and neuroscience.

[237]  R. Sacco,et al.  Lipoprotein-Associated Phospholipase A2 Activity and Risk of Recurrent Stroke , 2008, Cerebrovascular Diseases.

[238]  L. Liaudet,et al.  Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.

[239]  L. Stead,et al.  S100 as a Marker of Acute Brain Ischemia: A Systematic Review , 2008, Neurocritical care.

[240]  F. Altieri,et al.  Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans , 2017, Oxidative medicine and cellular longevity.

[241]  N. Greig,et al.  Cerebrovascular Biology and the various neural barriers: challenges and future directions. , 1999, Neurosurgery.

[242]  J. Arenillas,et al.  Matrix Metalloproteinase Expression Is Related to Hemorrhagic Transformation After Cardioembolic Stroke , 2001, Stroke.

[243]  L. Jennings.  Role of platelets in atherothrombosis. , 2009, The American journal of cardiology.

[244]  A. Hofman,et al.  High von Willebrand Factor Levels Increase the Risk of Stroke: The Rotterdam Study , 2010, Stroke.

[245]  R. Detels,et al.  Variables That Affect Assays for Plasma Cytokines and Soluble Activation Markers , 1999, Clinical Diagnostic Laboratory Immunology.

[246]  K. Tracey,et al.  DAMP Signaling is a Key Pathway Inducing Immune Modulation after Brain Injury , 2015, The Journal of Neuroscience.

[247]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[248]  J.L. Zhang,et al.  Plasma copeptin and long‐term outcomes in acute ischemic stroke , 2013, Acta neurologica Scandinavica.

[249]  M. Linnik,et al.  Evidence Supporting a Role for Programmed Cell Death in Focal Cerebral Ischemia in Rats , 1993, Stroke.

[250]  Natalia S. Rost,et al.  Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Study , 2001, Stroke.

[251]  L. Desender,et al.  ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice. , 2016, Blood.

[252]  Peter Nilsson,et al.  Systematic antibody and antigen-based proteomic profiling with microarrays , 2011, Expert review of molecular diagnostics.

[253]  R. Higashida,et al.  Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke , 2001, Neurology.

[254]  G. Lip,et al.  Additive Role of Plasma von Willebrand Factor Levels to Clinical Factors for Risk Stratification of Patients With Atrial Fibrillation , 2006, Stroke.

[255]  F. Peyvandi,et al.  Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies , 2013, Thrombosis and Haemostasis.

[256]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[257]  D. Grenache,et al.  Comparison of three assays for quantifying S-100B in serum. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[258]  W. Freeman,et al.  Stroke prevention in atrial fibrillation and other major cardiac sources of embolism. , 2008, Neurologic clinics.

[259]  Ian Todd,et al.  ELISA in the multiplex era: Potentials and pitfalls , 2015, Proteomics. Clinical applications.

[260]  J. Struck,et al.  Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. , 2007, The Journal of clinical endocrinology and metabolism.

[261]  Y. Ben-Ari,et al.  Apoptosis and Necrosis after Reversible Focal Ischemia: An in Situ DNA Fragmentation Analysis , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[262]  R. Sacco,et al.  High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. , 2006, Archives of internal medicine.

[263]  F F SAVERIO,et al.  [Cerebral circulation]. , 1954, Omnia therapeutica. Supplemento.

[264]  M. Wadhwa,et al.  Standardization and calibration of cytokine immunoassays: meeting report and recommendations. , 1997, Cytokine.

[265]  R. Rava,et al.  Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. , 2014, Clinical chemistry.

[266]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[267]  A. Chauhan,et al.  The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. , 2009, Blood.

[268]  B. S. Sørensen,et al.  An evaluation of multiplex bead-based analysis of cytokines and soluble proteins in archived lithium heparin plasma, EDTA plasma and serum samples , 2016, Scandinavian journal of clinical and laboratory investigation.

[269]  S. Lakhan,et al.  Inflammatory mechanisms in ischemic stroke: therapeutic approaches , 2009, Journal of Translational Medicine.

[270]  M. Di Napoli,et al.  C-Reactive Protein in Ischemic Stroke: An Independent Prognostic Factor , 2001, Stroke.

[271]  Standardization of high-sensitivity immunoassays for measurement of C-reactive protein; II: Two approaches for assessing commutability of a reference material. , 2009, Clinical chemistry.

[272]  N. Rifai,et al.  Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Phase I: evaluation of secondary reference materials. , 2003, Clinical chemistry.

[273]  J. García,et al.  Excitotoxicity and Oxidative Stress in Acute Stroke , 2016 .

[274]  T. Tatlisumak,et al.  The blood–brain barrier is continuously open for several weeks following transient focal cerebral ischemia , 2008, Neuroscience.

[275]  Faisal Javed,et al.  Some new prospects in the understanding of the molecular basis of the pathogenesis of stroke , 2007, Experimental Brain Research.

[276]  J. Broderick,et al.  Association of Serial Biochemical Markers With Acute Ischemic Stroke: The National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study , 2006, Stroke.

[277]  C. Iadecola,et al.  The immunology of stroke: from mechanisms to translation , 2011, Nature Medicine.

[278]  R. Dean,et al.  Stable markers of oxidant damage to proteins and their application in the study of human disease. , 1999, Free radical biology & medicine.

[279]  Á. Chamorro,et al.  Catecholamines, infection, and death in acute ischemic stroke , 2007, Journal of the Neurological Sciences.

[280]  P. Langhorne,et al.  Associations of Inflammatory and Haemostatic Biomarkers with Poor Outcome in Acute Ischaemic Stroke , 2009, Cerebrovascular Diseases.

[281]  F. Sharp,et al.  Hemorrhagic Transformation after Ischemic Stroke in Animals and Humans , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[282]  A. Folsom,et al.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. , 1999, Circulation.

[283]  M. D. Maat.  Effects of Diet, Drugs, and Genes on Plasma Fibrinogen Levels , 2001 .

[284]  P. Couraud,et al.  Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation , 2012, Fluids and Barriers of the CNS.

[285]  E. Moldoveanu,et al.  Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[286]  M. Cipolla.  Integrated Systems Physiology: From Molecule to Function , 2009 .

[287]  P. Sandercock,et al.  Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | NOVA. The University of Newcastle's Digital Repository , 2014 .

[288]  Cathie Sudlow,et al.  Lacunar stroke is associated with diffuse blood–brain barrier dysfunction , 2009, Annals of neurology.

[289]  P. Langhorne,et al.  d-Dimer Predicts Early Clinical Progression in Ischemic Stroke: Confirmation Using Routine Clinical Assays , 2006, Stroke.

[290]  R. Banks.  Measurement of Cytokines in Clinical Samples Using Immunoassays: Problems and Pitfalls , 2000, Critical reviews in clinical laboratory sciences.

[291]  Dianne Langford,et al.  Blood biomarkers for brain injury: What are we measuring? , 2016, Neuroscience & Biobehavioral Reviews.

[292]  A. Alexandrov,et al.  Matrix metalloproteinase-9: dual role and temporal profile in intracerebral hemorrhage. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[293]  Jeffery L. Carter,et al.  Sympathetic modulation of immunity: relevance to disease. , 2008, Cellular immunology.

[294]  Chad M. Miller,et al.  Impact of Infection on Stroke Morbidity and Outcomes , 2016, Current Neurology and Neuroscience Reports.

[295]  G. Chrousos,et al.  The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. , 1995, The New England journal of medicine.

[296]  D. Heistad,et al.  Regulation of large cerebral arteries and cerebral microvascular pressure. , 1990, Circulation research.

[297]  J. Montaner,et al.  Neuroinflammatory biomarkers: From stroke diagnosis and prognosis to therapy. , 2016, Biochimica et biophysica acta.

[298]  R. Gamelli,et al.  Dynamic norepinephrine alterations in bone marrow: evidence of functional innervation , 1999, Journal of Neuroimmunology.

[299]  J. Sejvar,et al.  Risk of Elective Major Noncardiac Surgery After Coronary Stent Insertion , 2012 .

[300]  E. Lo,et al.  Extracellular proteolytic pathophysiology in the neurovascular unit after stroke , 2004, Neurological research.

[301]  R. Bischoff,et al.  Physiology and pathophysiology of matrix metalloproteases , 2010, Amino Acids.

[302]  U. Andersson,et al.  HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease , 2012, Nature Reviews Rheumatology.

[303]  G. Lip,et al.  Prognostic Value of Plasma von Willebrand Factor and Soluble P-Selectin as Indices of Endothelial Damage and Platelet Activation in 994 Patients With Nonvalvular Atrial Fibrillation , 2003, Circulation.

[304]  H. Steinmetz,et al.  Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. , 2007, Stroke.

[305]  A. Hofman,et al.  Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. , 2015, Blood.

[306]  Johanna E. Camara,et al.  Standardizing 25-hydroxyvitamin D values from the Canadian Health Measures Survey. , 2015, The American journal of clinical nutrition.

[307]  J. Ioannidis,et al.  Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.

[308]  A. Meisel,et al.  Impact of infections on long-term outcome after severe middle cerebral artery infarction , 2012, Journal of the Neurological Sciences.

[309]  Tilman Grune,et al.  Clinical Relevance of Biomarkers of Oxidative Stress , 2015, Antioxidants & redox signaling.

[310]  Hui Sun,et al.  Metabolomics for Biomarker Discovery: Moving to the Clinic , 2015, BioMed research international.

[311]  C. Serhan,et al.  Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. , 2010, Circulation research.

[312]  J. Montaner,et al.  Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns , 2016, Neurotherapeutics.

[313]  A. Strong,et al.  The concepts of thresholds of ischaemia in relation to brain structure and function. , 1977, Journal of clinical pathology. Supplement.

[314]  Grace Y Chen,et al.  Sterile inflammation: sensing and reacting to damage , 2010, Nature Reviews Immunology.

[315]  U. Keil,et al.  Determinants of plasma fibrinogen: relation to body weight, waist-to-hip ratio, smoking, alcohol, age, and sex. Results from the second MONICA Augsburg survey 1989-1990. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[316]  Jie Shuai,et al.  Plasma D-Dimer Levels Are Associated with Stroke Subtypes and Infarction Volume in Patients with Acute Ischemic Stroke , 2014, PloS one.

[317]  K. Muir,et al.  Thrombolysis and thrombectomy for acute ischaemic stroke , 2017, Clinical medicine.

[318]  G. Jickling,et al.  Breaking down barriers to identify hemorrhagic transformation in ischemic stroke , 2012, Neurology.

[319]  Qing Wang,et al.  The inflammatory response in stroke , 2007, Journal of Neuroimmunology.

[320]  R. Rodrigo,et al.  Oxidative Stress-Related Biomarkers in Essential Hypertension and Ischemia-Reperfusion Myocardial Damage , 2013, Disease markers.

[321]  I. Graham,et al.  von Willebrand factor in CHD and stroke: Relationships and therapeutic implications , 2007, Current treatment options in cardiovascular medicine.

[322]  Shyam Prabhakaran,et al.  Acute stroke intervention: a systematic review. , 2015, JAMA.

[323]  Y. Ben-Ari,et al.  Apoptotic features of selective neuronal death in ischemia, epilepsy and gpI20 toxicity , 1996, Trends in Neurosciences.

[324]  I. Khatri,et al.  Intraarterial thrombolysis with reteplase in acute ischaemic stroke in a Pakistani center. , 2008, JPMA. The Journal of the Pakistan Medical Association.

[325]  J. Mohr.  Lacunar stroke. , 1986, Hypertension.

[326]  J. Montaner,et al.  The Proteome of Human Brain After Ischemic Stroke , 2010, Journal of neuropathology and experimental neurology.

[327]  Talvensaari-Mattila Anne,et al.  The Sample Type used Affects the Levels of Gelatinases (MMP-2 and -9) and their Inhibitors (TIMP-1 and -2) in Circulating Blood of Healthy Controls and Breast Cancer Patients , 2007, Biomarker insights.

[328]  Tian Feng,et al.  Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. , 2013, The Journal of clinical investigation.

[329]  M. Serteser,et al.  Biological variations of ADAMTS13 and von Willebrand factor in human adults , 2014, Biochemia medica.

[330]  P. Deb,et al.  Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. , 2010, Pathophysiology : the official journal of the International Society for Pathophysiology.

[331]  L. Pantoni,et al.  Cytokines and cell adhesion molecules in cerebral ischemia: experimental bases and therapeutic perspectives. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[332]  S. Soper,et al.  Current and future bioanalytical approaches for stroke assessment. , 2015, Bioanalysis.

[333]  N. Rothwell,et al.  Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome , 2004, BMC neurology.

[334]  Z. Tian,et al.  Plasma copeptin and functional outcome in patients with ischemic stroke and type 2 diabetes. , 2016, Journal of diabetes and its complications.

[335]  K. Tracey,et al.  HMGB1 is a therapeutic target for sterile inflammation and infection. , 2011, Annual review of immunology.

[336]  G. Kuchel,et al.  ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[337]  J. Struck,et al.  Copeptin: clinical use of a new biomarker , 2008, Trends in Endocrinology & Metabolism.

[338]  S. Avrameas,et al.  A method for quantitative determination of cellular immunoglobulins by enzyme‐labeled antibodies , 1971, European journal of immunology.

[339]  M. Yenari.  Pathophysiology of acute ischemic stroke. , 2004, Cleveland Clinic journal of medicine.

[340]  Neuroimaging markers of hemorrhagic risk with stroke reperfusion therapy , 2012, Neurology.

[341]  P. Guedes de Pinho,et al.  Metabolomics analysis for biomarker discovery: advances and challenges. , 2012, Current medicinal chemistry.

[342]  T. Wilckens,et al.  Glucocorticoids and immune function: unknown dimensions and new frontiers. , 1997, Immunology today.

[343]  F. Aichner,et al.  Prognostic value of admission C-reactive protein in stroke patients undergoing IV thrombolysis , 2008, Journal of Neurology.

[344]  K. Waterloo,et al.  Analysis of protein S-100B in serum: a methodological study , 2006, Clinical chemistry and laboratory medicine.

[345]  P. Heuschmann,et al.  Predictors of in-hospital mortality and attributable risks of death after ischemic stroke: the German Stroke Registers Study Group. , 2004, Archives of internal medicine.

[346]  J. Bamford,et al.  Classification and natural history of clinically identifiable subtypes of cerebral infarction , 1991, The Lancet.

[347]  E. Engvall,et al.  Enzyme-linked immunosorbent assay. II. Quantitative assay of protein antigen, immunoglobulin G, by means of enzyme-labelled antigen and antibody-coated tubes. , 1971, Biochimica et biophysica acta.

[348]  T. Neumann-Haefelin,et al.  Serum S100B Predicts a Malignant Course of Infarction in Patients With Acute Middle Cerebral Artery Occlusion , 2004, Stroke.

[349]  L Bozzao,et al.  Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. , 1999, Stroke.

[350]  A. Chauhan,et al.  The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. , 2008, Blood.

[351]  S. Johnston,et al.  Frequency and determinants of pneumonia and urinary tract infection during stroke hospitalization. , 2006, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[352]  B. Hyman,et al.  Apoptotic and non-apoptotic roles of caspases in neuronal physiology and pathophysiology , 2012, Nature Reviews Neuroscience.

[353]  Ronney B. Panerai,et al.  The Longitudinal Evolution of Cerebral Blood Flow Regulation after Acute Ischaemic Stroke , 2014, Cerebrovascular Diseases Extra.

[354]  P. D. de Groot,et al.  von Willebrand factor propeptide and the occurrence of a first ischemic stroke , 2010, Journal of thrombosis and haemostasis : JTH.

[355]  B. Woodhams,et al.  Stability of coagulation proteins in frozen plasma , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[356]  G. Lowe,et al.  Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and Stroke: The Edinburgh Artery Study , 2007, Circulation.

[357]  G. Di Minno,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[358]  T. Neumann-Haefelin,et al.  Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction. , 2005, Archives of neurology.

[359]  M. Rizzo,et al.  Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. , 2006, Stroke.

[360]  Jae Min Kim,et al.  Prognostic role of copeptin after stroke: A systematic review and meta-analysis of observational studies , 2015, Scientific Reports.

[361]  J. Arenillas,et al.  Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Study , 2007, Stroke.

[362]  B. Lämmle,et al.  Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13) , 2008, Journal of thrombosis and haemostasis : JTH.

[363]  M. Sitzer,et al.  Characterisation of the Diagnostic Window of Serum Glial Fibrillary Acidic Protein for the Differentiation of Intracerebral Haemorrhage and Ischaemic Stroke , 2008, Cerebrovascular Diseases.

[364]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[365]  W. White,et al.  Novel Diagnostic Test for Acute Stroke , 2003, Stroke.

[366]  Robert H Christenson,et al.  Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. , 2010, Clinical chemistry.

[367]  S. Kazui,et al.  Mortality and Cause of Death after Hospital Discharge in 10,981 Patients with Ischemic Stroke and Transient Ischemic Attack , 2005, Cerebrovascular Diseases.

[368]  Á. Chamorro,et al.  Infection After Acute Ischemic Stroke: A Manifestation of Brain-Induced Immunodepression , 2007, Stroke.

[369]  N. Kucher,et al.  Biological variation of established and novel biomarkers for atherosclerosis: Results from a prospective, parallel-group cohort study. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[370]  E. Kilpatrick,et al.  Reference measurement procedure development for C-reactive protein in human serum. , 2009, Analytical chemistry.

[371]  G. Lowe,et al.  Guidelines on fibrinogen assays , 2003, British journal of haematology.

[372]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[373]  F. Maquart,et al.  Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice , 2005, Clinical chemistry and laboratory medicine.

[374]  D. Tsikas.  Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges. , 2017, Analytical biochemistry.

[375]  Heesang Song,et al.  High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes: a comparable and additive study , 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[376]  P. Koudstaal,et al.  International Epidemiology of Intracerebral Hemorrhage , 2012, Current Atherosclerosis Reports.

[377]  J. Goetze,et al.  Comparison of automated von Willebrand factor activity assays. , 2015, Thrombosis research.

[378]  B. van Weemen,et al.  Immunoassay using antigen—enzyme conjugates , 1971, FEBS letters.

[379]  Ferdousi Chowdhury,et al.  Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. , 2009, Journal of immunological methods.

[380]  Carl Nathan,et al.  Nonresolving Inflammation , 2010, Cell.

[381]  Maren S Fragala,et al.  Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research , 2010, Current opinion in clinical nutrition and metabolic care.

[382]  J. Liao,et al.  Potential serum biomarkers in the pathophysiological processes of stroke , 2014, Expert review of neurotherapeutics.

[383]  Jennifer G. Robinson,et al.  Can Biomarkers Identify Women at Increased Stroke Risk? The Women's Health Initiative Hormone Trials , 2007, PLoS clinical trials.

[384]  Mark D. Huffman,et al.  Heart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association , 2016, Circulation.

[385]  J. Horáček,et al.  Biochip array technology and evaluation of serum levels of multiple cytokines and adhesion molecules in patients with newly diagnosed acute myeloid leukemia. , 2014, Experimental oncology.

[386]  W. de Jager,et al.  Solid-phase and bead-based cytokine immunoassay: a comparison. , 2006, Methods.

[387]  Ian Todd,et al.  Utility, reliability and reproducibility of immunoassay multiplex kits. , 2013, Methods.

[388]  R. Schneppenheim,et al.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[389]  G. Lippi,et al.  Harmonisation of D-dimer - A call for action. , 2016, Thrombosis research.

[390]  C. Woiciechowsky,et al.  Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. , 2002, The Journal of trauma.

[391]  U. Demkow,et al.  Cross-talk between the inflammatory response, sympathetic activation and pulmonary infection in the ischemic stroke , 2014, Journal of Neuroinflammation.

[392]  G. Lip,et al.  Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. , 2005, Thrombosis research.

[393]  U. Dirnagl,et al.  Stroke-induced immunodepression and post-stroke infections: Lessons from the preventive antibacterial therapy in stroke trial , 2009, Neuroscience.

[394]  D. Webb,et al.  Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis , 2013, Cerebrovascular Diseases.

[395]  David J. Begley,et al.  Structure and function of the blood–brain barrier , 2010, Neurobiology of Disease.

[396]  O. Kim,et al.  Plasma heart-type fatty acid binding protein level in acute ischemic stroke: Comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome , 2013, Clinical Neurology and Neurosurgery.

[397]  A. Ferbert,et al.  Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. , 2012, Clinical chemistry.